Esperion Announces the Appointment of Tracy M. Woody to Board of Directors
30 mai 2019 16h15 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Tracy M. Woody as a Class I director, with a term expiring at the 2020 meeting of...
Esperion to Participate in Upcoming Investor Conferences
28 mai 2019 07h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 28, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences:...
Esperion to Participate in Upcoming Investor Conferences
10 mai 2019 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 10, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences:...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results
08 mai 2019 07h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the first quarter ended March...
Esperion to Host Analyst and Investor Day Event on May 30
07 mai 2019 05h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 07, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will host an analyst and investor day on Thursday, May 30, 2019, beginning at 9:00 a.m....
Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
05 mai 2019 17h00 HE
|
Esperion Therapeutics, Inc.
– Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver –– February 21, 2020 PDUFA Target Date Goal for Bempedoic Acid...
Esperion to Present at the Needham & Company 18th Annual Healthcare Conference
02 avr. 2019 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 02, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient,...
Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results
01 avr. 2019 16h15 HE
|
Esperion Therapeutics, Inc.
– Study 3 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant –– Over 24-Weeks, Bempedoic Acid Was Observed to be Safe,...
Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions
18 mars 2019 09h20 HE
|
Esperion Therapeutics, Inc.
–Study 2 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP––Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Adverse Event Profile was...
Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
13 mars 2019 17h05 HE
|
Esperion Therapeutics, Inc.
– Study 1 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP –– Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated, and Did Not Lead to Higher...